North Chicago, Ill.-based AbbVie signed a partnership deal with Ablynx for the drug — called vobarilizumab — three years ago. AbbVie offered a $175 million upfront payment, with $665 million payable in future milestones if it opts to license the drug.
The drug targets a protein called interleukin 6, which contributes to the inflammation involved with rheumatoid arthritis.
During the 12-week Phase II clinical trial, about 41 percent of patients taking vobarilizumab demonstrated clinical remission from the disease.
“We’re getting really stand-out data, which is great, and it is the first step for us in providing a data package to AbbVie, who will decide later in the year whether to take up their option and license the product,” Edwin Moses, PhD, CEO of Ablynx, said, according to Reuters.
More articles on the drug market:
Pfizer agrees to acknowledge addiction risks in opioid marketing
Sanofi, U.S. Army partner to speed up Zika vaccine development
Drugmakers hesitant to let generic rival Teva join PhRMA
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.